Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Real-time Estimate Cboe BZX
Other stock markets
 12:12:21 2024-05-02 pm EDT 		5-day change 1st Jan Change
14.25 USD +3.19% Intraday chart for Viridian Therapeutics, Inc. +12.36% -34.48%
Apr. 16 Foghorn Therapeutics Names Kristian Humer CFO MT
Mar. 21 B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
PR
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BU
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
AQ
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
BU
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
BU
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
BU
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
BU
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Viridian Therapeutics : Subcutaneous IGF-1R program selection Presentation
PU
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
BU
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
BU
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
BU
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
BU
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. News Viridian Therapeutics, Inc.
  5. Press Releases